Form 4: Thermo Fisher Scientific Director Increases Stake Through Deferred Compensation Plan

Jennifer M. Johnson, a Director at Thermo Fisher Scientific Inc., acquired 76.54 phantom stock units as part of the company's deferred compensation plan, increasing her beneficial ownership to 474.05 units.

Summary

• Jennifer M. Johnson, a Director of Thermo Fisher Scientific Inc. (TMO), acquired 76.54 phantom stock units.
• The transaction occurred on June 28, 2025, with each unit valued at $408.28.
• The acquisition was made pursuant to the Issuer's Deferred Compensation Plan for Directors, where directors' retainers are deferred quarterly as Common Stock units based on the closing stock price.
• Following this transaction, Jennifer M. Johnson beneficially owns a total of 474.05 phantom stock units.
• These phantom stock units are convertible into Thermo Fisher Scientific Common Stock on a 1-for-1 basis.
• The shares are distributable as stock upon cessation of director service (for any reason) or a change of control.

Sentiment

Score: 5

Explanation: The document is a routine Form 4 filing detailing a director's acquisition of phantom stock units as part of a deferred compensation plan, which is a neutral event in terms of company performance or outlook.

Positives

• Director Jennifer M. Johnson increased her beneficial ownership in Thermo Fisher Scientific, which aligns her interests further with those of the shareholders.
• The acquisition is part of a structured Deferred Compensation Plan for Directors, indicating a standard and transparent approach to executive compensation and retention.

Future Outlook

NA

Management Comments

• Reporting Person Jennifer M. Johnson is the President, Chief Executive Officer, and a Director of Franklin Resources, Inc., a global investment management organization operating as Franklin Templeton.
• Franklin Templeton subsidiaries manage investment products and client accounts that hold equity securities of Thermo Fisher Scientific in the ordinary course of business.
• Jennifer M. Johnson disclaims beneficial ownership of such securities managed by Franklin Templeton subsidiaries.

Industry Context

This Form 4 filing reflects a standard insider transaction related to director compensation, common across publicly traded companies. It does not provide insights into broader industry trends or competitive dynamics within the life sciences or analytical instruments sector.

Stakeholder Impact

• Shareholders: The acquisition of phantom stock units by a director through a deferred compensation plan aligns the director's interests with those of the shareholders, potentially fostering long-term value creation.

Next Steps

• Shares underlying the phantom stock units will be distributable as stock upon cessation of director service or a change of control.

Key Dates

Keywords

Thermo Fisher Scientific, TMO, Form 4, Insider Transaction, Director Compensation, Phantom Stock Units, Deferred Compensation, Jennifer M. Johnson